Ligand Pharmaceuticals Inc (LGND) 65.00 $LGND
Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
Business Wire - Mon May 12, 7:02AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has earned a $150,000 milestone payment from SAGE Therapeutics (SAGE) relating to the earlier commencement by SAGE of a Phase 1/2 clinical trial of SAGE-547 for the treatment of super-refractory status epilepticus (SRSE), a life-threatening seizure condition in which the brain is in a state of persistent seizure.
Ligand Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 7:31AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.
Clinical Winners and Losers: Spectrum Pharmaceuticals and Cytokinetics
Cory Renauer, The Motley Fool - Motley Fool - Fri May 02, 8:30AM CDT
Clinical trial highlights took a back seat last week to the stream of blockbuster deals in the health care sector. Still, there was a big winner and a big loser -- even if they flew relatively under the radar. Spectrum Pharmaceuticals was, in my...
Ligand Partner GlaxoSmithKline Gains Priority Review Designation for Promacta(TM)/Revolade(TM) for Severe Aplastic Anemia
Business Wire - Wed Apr 30, 6:30AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has granted its partner GlaxoSmithKline plc (LSE:GSK) Priority Review designation for Promacta(TM)/Revolade(TM) (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
Spectrum Pharma Candidate Gets Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:50PM CDT
Spectrum Pharmaceuticals (SPPI) announced encouraging results from a phase II pivotal study on captisol-enabled melphalan.
Ligand's Partner Spectrum Pharmaceuticals Reports Captisol-Enabled Melphalan Meets Primary Endpoint in Pivotal Trial
Business Wire - Wed Apr 23, 6:10AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its Captisol-enabled(TM) (propylene glycol-free) Melphalan (CE Melphalan) development and commercial partner Spectrum Pharmaceuticals (NASDAQ: SPPI) has reported that their pivotal trial of CE Melphalan met its primary endpoint.
Ligand to Participate in Three Upcoming Investor Conferences
Business Wire - Wed Apr 23, 6:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences:
Ligand to Report First Quarter Results on May 7th
Business Wire - Tue Apr 22, 6:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today plans to report first quarter 2014 financial results on May 7, 2014. Ligand's President and CEO John Higgins, Executive Vice President and COO Matt Foehr and Vice President of Finance & Strategy and CFO Nishan De Silva will host the conference call.
Ligand Pharmaceuticals Shares Down 9.4% Since SmarTrend's Sell Call (LGND)
Comtex SmarTrend(R) - Mon Apr 14, 9:29AM CDT
SmarTrend identified a Downtrend for Ligand Pharmaceuticals (NASDAQ:LGND) on March 26th, 2014 at $69.34. In approximately 3 weeks, Ligand Pharmaceuticals has returned 9.39% as of today's recent price of $62.83.
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst.
Healthcare Companies Announce Awards, Partnerships, Milestone Payments, and Conference Schedules - Analyst Notes on Inovio, LifePoint, Mallinckrodt, Ligand, and Theravance
PR Newswire - Wed Apr 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Inovio Pharmaceuticals, Inc. (NYSEMKT: INO), LifePoint Hospitals Inc. (NASDAQ: LPNT), Mallinckrodt plc (NYSE: MNK), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), and Theravance Inc. (NASDAQ: THRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Insider Trading Alert - VLO, LGND And DAR Traded By Insiders
at The Street - Fri Mar 21, 9:30AM CDT
Stocks with insider trader activity include VLO, LGND and DAR
Milestone Payment for Ligand Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 4:30PM CDT
Ligand Pharma receives milestone payment from Merck.
Ligand Pharmaceuticals triggers USD1m milestone payment upon US FDA's approval of Merck's NOXAFIL Injection
M2 - Tue Mar 18, 5:57AM CDT
Biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) said on Monday that it expects a USD1m milestone payment following the US Food and Drug Administration's (FDA) approval of Merck's NOXAFIL (posaconazole) injection (18 mg/ml).
Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck's NOXAFIL(R) (posaconazole) Injection for Intravenous Use, a New Captisol-enabled Formulation
Business Wire - Mon Mar 17, 7:15AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that it has earned a $1 million milestone payment as a result of the recent U.S. Food and Drug Administration (FDA) approval of Merck's NOXAFIL(R) (posaconazole) injection (18 mg/mL). This is a new Captisol(R)-enabled formulation of NOXAFIL for intravenous (IV) use. Ligand will sell Captisol to Merck for this product under a commercial supply agreement.
Bright Outlook at Ligand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:30AM CDT
Ligand provided a rosy outlook at the 2014 Roth Healthcare conference.
Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference
Business Wire - Tue Mar 11, 3:15PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented today at the Roth Capital Conference in Dana Point, California, where it reviewed its business and financial highlights, its unique R&D model and selected un-partnered programs, and provided partnering case studies.
Ligand Pharmaceuticals' NDA for carbamazepine IV accepted for review by US FDA
M2 - Tue Mar 11, 7:19AM CDT
US-based biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) said on Monday that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational intravenous formulation of the anti-epileptic drug, carbamazepine.
Commit To Buy Ligand Pharmaceuticals At $65, Earn 22.6% Annualized Using Options
at The Street - Mon Mar 10, 10:45AM CDT
Investors considering a purchase of Ligand Pharmaceuticals Inc stock, but tentative about paying the going market price of $69.92/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
Captisol(R) Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV
Business Wire - Mon Mar 10, 9:12AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Captisol(R) licensee Lundbeck LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug carbamazepine. An action letter is anticipated before the end of 2014. Carbella(TM) (carbamazepine) Injection is the proposed U.S. trade name. With acceptance of the NDA filing, Ligand earns a $200,000 milestone payment.
Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
Business Wire - Mon May 12, 7:02AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has earned a $150,000 milestone payment from SAGE Therapeutics (SAGE) relating to the earlier commencement by SAGE of a Phase 1/2 clinical trial of SAGE-547 for the treatment of super-refractory status epilepticus (SRSE), a life-threatening seizure condition in which the brain is in a state of persistent seizure.
Ligand Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 7:31AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.
Clinical Winners and Losers: Spectrum Pharmaceuticals and Cytokinetics
Cory Renauer, The Motley Fool - Motley Fool - Fri May 02, 8:30AM CDT
Clinical trial highlights took a back seat last week to the stream of blockbuster deals in the health care sector. Still, there was a big winner and a big loser -- even if they flew relatively under the radar. Spectrum Pharmaceuticals was, in my...
Ligand Partner GlaxoSmithKline Gains Priority Review Designation for Promacta(TM)/Revolade(TM) for Severe Aplastic Anemia
Business Wire - Wed Apr 30, 6:30AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has granted its partner GlaxoSmithKline plc (LSE:GSK) Priority Review designation for Promacta(TM)/Revolade(TM) (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
Spectrum Pharma Candidate Gets Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:50PM CDT
Spectrum Pharmaceuticals (SPPI) announced encouraging results from a phase II pivotal study on captisol-enabled melphalan.
Ligand's Partner Spectrum Pharmaceuticals Reports Captisol-Enabled Melphalan Meets Primary Endpoint in Pivotal Trial
Business Wire - Wed Apr 23, 6:10AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its Captisol-enabled(TM) (propylene glycol-free) Melphalan (CE Melphalan) development and commercial partner Spectrum Pharmaceuticals (NASDAQ: SPPI) has reported that their pivotal trial of CE Melphalan met its primary endpoint.
Ligand to Participate in Three Upcoming Investor Conferences
Business Wire - Wed Apr 23, 6:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences:
Ligand to Report First Quarter Results on May 7th
Business Wire - Tue Apr 22, 6:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today plans to report first quarter 2014 financial results on May 7, 2014. Ligand's President and CEO John Higgins, Executive Vice President and COO Matt Foehr and Vice President of Finance & Strategy and CFO Nishan De Silva will host the conference call.
Ligand Pharmaceuticals Shares Down 9.4% Since SmarTrend's Sell Call (LGND)
Comtex SmarTrend(R) - Mon Apr 14, 9:29AM CDT
SmarTrend identified a Downtrend for Ligand Pharmaceuticals (NASDAQ:LGND) on March 26th, 2014 at $69.34. In approximately 3 weeks, Ligand Pharmaceuticals has returned 9.39% as of today's recent price of $62.83.
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst. Healthcare Companies Announce Awards, Partnerships, Milestone Payments, and Conference Schedules - Analyst Notes on Inovio, LifePoint, Mallinckrodt, Ligand, and Theravance
PR Newswire - Wed Apr 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Inovio Pharmaceuticals, Inc. (NYSEMKT: INO), LifePoint Hospitals Inc. (NASDAQ: LPNT), Mallinckrodt plc (NYSE: MNK), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), and Theravance Inc. (NASDAQ: THRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Insider Trading Alert - VLO, LGND And DAR Traded By Insiders
at The Street - Fri Mar 21, 9:30AM CDT
Stocks with insider trader activity include VLO, LGND and DAR
Milestone Payment for Ligand Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 4:30PM CDT
Ligand Pharma receives milestone payment from Merck.
Ligand Pharmaceuticals triggers USD1m milestone payment upon US FDA's approval of Merck's NOXAFIL Injection
M2 - Tue Mar 18, 5:57AM CDT
Biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) said on Monday that it expects a USD1m milestone payment following the US Food and Drug Administration's (FDA) approval of Merck's NOXAFIL (posaconazole) injection (18 mg/ml).
Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck's NOXAFIL(R) (posaconazole) Injection for Intravenous Use, a New Captisol-enabled Formulation
Business Wire - Mon Mar 17, 7:15AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that it has earned a $1 million milestone payment as a result of the recent U.S. Food and Drug Administration (FDA) approval of Merck's NOXAFIL(R) (posaconazole) injection (18 mg/mL). This is a new Captisol(R)-enabled formulation of NOXAFIL for intravenous (IV) use. Ligand will sell Captisol to Merck for this product under a commercial supply agreement.
Bright Outlook at Ligand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:30AM CDT
Ligand provided a rosy outlook at the 2014 Roth Healthcare conference.
Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference
Business Wire - Tue Mar 11, 3:15PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented today at the Roth Capital Conference in Dana Point, California, where it reviewed its business and financial highlights, its unique R&D model and selected un-partnered programs, and provided partnering case studies.
Ligand Pharmaceuticals' NDA for carbamazepine IV accepted for review by US FDA
M2 - Tue Mar 11, 7:19AM CDT
US-based biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) said on Monday that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational intravenous formulation of the anti-epileptic drug, carbamazepine.
Commit To Buy Ligand Pharmaceuticals At $65, Earn 22.6% Annualized Using Options
at The Street - Mon Mar 10, 10:45AM CDT
Investors considering a purchase of Ligand Pharmaceuticals Inc stock, but tentative about paying the going market price of $69.92/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
Captisol(R) Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV
Business Wire - Mon Mar 10, 9:12AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Captisol(R) licensee Lundbeck LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug carbamazepine. An action letter is anticipated before the end of 2014. Carbella(TM) (carbamazepine) Injection is the proposed U.S. trade name. With acceptance of the NDA filing, Ligand earns a $200,000 milestone payment.
